Emmaus Life Sciences Inc (OTCQX:EMMA) CEO Yutaka Niihara tells Proactive that it has launched an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript IP Holdings, LLC. The telehealth program capitalizes on the expansion of telemedicine in the US to afford patients and providers online access to Endari, Emmaus' prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, the commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease said.
Emmaus Life Sciences launches full-service telehealth solution with online access to Endari
